Medical Education Library

Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment

J Fam Pract. 2017 October;66(10)
This supplement was sponsored by Primary Care Education Consortium and Primary Care Metabolic Group and was supported by funding from Novo Nordisk Inc.

 

Click Here to Read the Supplement.

Topics include:

  • Medications for Type 2 Diabetes Mellitus: A Work in Progress
  • Role of Injectable Medications in Type 2 Diabetes Treatment
  • Basal Insulins
  • Glucagon-Like Peptide-1 Receptor Agonists
  • Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist

Click Here to Read the Supplement.

Recommended Reading

Alirocumab’s ODYSSEY continues: Efficacy unaffected by insulin, beats fenofibrate
MDedge Family Medicine
CONCEPTT: Continuous glucose monitoring during pregnancy benefits baby
MDedge Family Medicine
Roux-en-Y gastric bypass produced durable clinical improvements at 12 years
MDedge Family Medicine
Is obesity a disease?
MDedge Family Medicine
Empagliflozin’s effects independent of CVD risk factors
MDedge Family Medicine
Delayed-release metformin proves promising for diabetic renal disease
MDedge Family Medicine
FDA approves first non–finger-stick glucose monitoring system
MDedge Family Medicine
Skin autofluorescence predicts 4-year CVD risk in diabetes
MDedge Family Medicine
New ADA hypertension and diabetes treatment guide features visual aid
MDedge Family Medicine
Many years on metformin linked to anemia risk
MDedge Family Medicine